Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
BAX · NYSE · Healthcare
Fundamental quality
32
out of 100
Baxter International Inc is going through a tough financial stretch: it hasn't been profitable over the last twelve months and its revenue is shrinking. On fundamental quality it scores 32 out of 100, profiling it as a company with demanding fundamentals. Its weakest area is its growth (revenue -0.3%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Baxter International makes essential hospital products: IV fluids and solutions, infusion pumps, clinical nutrition and renal therapies. It is a hospital's plumbing: invisible when it works, critical when it's missing.
Revenue growth: -0.3%
Net margin: -9.3% · ROE: -17.1%
Net debt/EBITDA: 10.73x · FCF: 7%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 11,673 | 1,102 | 1,159 | 2,503 |
| 2021 | 12,146 | 1,284 | 1,531 | 15,104 |
| 2022 | 10,057 | -2,433 | 834 | 15,380 |
| 2023 | 10,360 | 2,656 | 1,294 | 10,777 |
| 2024 | 10,636 | -649 | 573 | 13,542 |
| 2025 | 11,244 | -957 | 332 | 7,473 |
Between 2020 and 2025, revenue went from $11,673M to $11,244M (-4%) and net income went from $1,102M to -$957M (-187%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$0.52
per share, yearly
104.8% of free cash flow
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Baxter International Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Baxter International Inc a good company to invest in?
In terms of business quality, Baxter International Inc scores 32 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Baxter International Inc a profitable company?
Over the last twelve months, no: Baxter International Inc posts a negative net margin (-9.3%).
Does Baxter International Inc have a lot of debt?
Yes, its leverage is high: net debt is 10.73 times its EBITDA, and it has been rising.
Is Baxter International Inc growing?
Its revenue has fallen 0.3% annualized in recent years.
Does Baxter International Inc generate cash?
Yes. It converts about 7% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · Teva Pharmaceutical Industries (TEVA) · Davita (DVA) · Henry Schein (HSIC) · see more →
The best Healthcare stocks by our model →
Compare Baxter International Inc with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Baxter International Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.